Literature DB >> 22362587

Differential expression of genes involved in the degeneration and regeneration pathways in mouse models for muscular dystrophies.

P C G Onofre-Oliveira1, A L F Santos, P M Martins, D Ayub-Guerrieri, M Vainzof.   

Abstract

The genetically determined muscular dystrophies are caused by mutations in genes coding for muscle proteins. Differences in the phenotypes are mainly the age of onset and velocity of progression. Muscle weakness is the consequence of myofiber degeneration due to an imbalance between successive cycles of degeneration/regeneration. While muscle fibers are lost, a replacement of the degraded muscle fibers by adipose and connective tissues occurs. Major investigation points are to elicit the involved pathophysiological mechanisms to elucidate how each mutation can lead to a specific degenerative process and how the regeneration is stimulated in each case. To answer these questions, we used four mouse models with different mutations causing muscular dystrophies, Dmd (mdx), SJL/J, Large (myd) and Lama2 (dy2J) /J, and compared the histological changes of regeneration and fibrosis to the expression of genes involved in those processes. For regeneration, the MyoD, Myf5 and myogenin genes related to the proliferation and differentiation of satellite cells were studied, while for degeneration, the TGF-β1 and Pro-collagen 1α2 genes, involved in the fibrotic cascade, were analyzed. The result suggests that TGF-β1 gene is activated in the dystrophic process in all the stages of degeneration, while the activation of the expression of the pro-collagen gene possibly occurs in mildest stages of this process. We also observed that each pathophysiological mechanism acted differently in the activation of regeneration, with distinctions in the induction of proliferation of satellite cells, but with no alterations in stimulation to differentiation. Dysfunction of satellite cells can, therefore, be an important additional mechanism of pathogenesis in the dystrophic muscle.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22362587     DOI: 10.1007/s12017-012-8172-3

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  35 in total

1.  Glycoprotein complex anchoring dystrophin to sarcolemma.

Authors:  M Yoshida; E Ozawa
Journal:  J Biochem       Date:  1990-11       Impact factor: 3.387

2.  A rapid PCR method for genotyping the Large(myd) mouse, a model of glycosylation-deficient congenital muscular dystrophy.

Authors:  Claudia A Browning; Prabhjit K Grewal; Christopher J Moore; Jane E Hewitt
Journal:  Neuromuscul Disord       Date:  2005-05       Impact factor: 4.296

3.  Synaptic plasticity in the dy2J mouse model of laminin alpha2-deficient congenital muscular dystrophy.

Authors:  J L Anderson; S I Head; J W Morley
Journal:  Brain Res       Date:  2005-04-25       Impact factor: 3.252

Review 4.  Animal models for genetic neuromuscular diseases.

Authors:  Mariz Vainzof; Danielle Ayub-Guerrieri; Paula C G Onofre; Poliana C M Martins; Vanessa F Lopes; Dinorah Zilberztajn; Lucas S Maia; Karen Sell; Lydia U Yamamoto
Journal:  J Mol Neurosci       Date:  2008-01-18       Impact factor: 3.444

5.  Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.

Authors:  Cheryl Longman; Martin Brockington; Silvia Torelli; Cecilia Jimenez-Mallebrera; Colin Kennedy; Nofal Khalil; Lucy Feng; Ravindra K Saran; Thomas Voit; Luciano Merlini; Caroline A Sewry; Susan C Brown; Francesco Muntoni
Journal:  Hum Mol Genet       Date:  2003-09-09       Impact factor: 6.150

6.  Increased expression of acetylcholine receptors in the diaphragm muscle of MDX mice.

Authors:  Paulo C Ghedini; Tânia A Viel; Luciana Honda; Maria Christina W Avellar; Rosely O Godinho; Maria Teresa R Lima-Landman; Antônio J Lapa; Caden Souccar
Journal:  Muscle Nerve       Date:  2008-12       Impact factor: 3.217

7.  Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration.

Authors:  Sean C Goetsch; Thomas J Hawke; Teresa D Gallardo; James A Richardson; Daniel J Garry
Journal:  Physiol Genomics       Date:  2003-08-15       Impact factor: 3.107

8.  Dysferlin protein analysis in limb-girdle muscular dystrophies.

Authors:  M Vainzof; L V Anderson; E M McNally; D B Davis; G Faulkner; G Valle; E S Moreira; R C Pavanello; M R Passos-Bueno; M Zatz
Journal:  J Mol Neurosci       Date:  2001-08       Impact factor: 2.866

9.  A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin.

Authors:  J M Ervasti; K P Campbell
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

Review 10.  Skeletal muscle stem cells.

Authors:  Jennifer C J Chen; David J Goldhamer
Journal:  Reprod Biol Endocrinol       Date:  2003-11-13       Impact factor: 5.211

View more
  17 in total

1.  Lack of the serum- and glucocorticoid-inducible kinase SGK1 improves muscle force characteristics and attenuates fibrosis in dystrophic mdx mouse muscle.

Authors:  Martin Steinberger; Michael Föller; Silke Vogelgesang; Mirjam Krautwald; Martin Landsberger; Claudia K Winkler; Joachim Kasch; Ernst-Martin Füchtbauer; Dietmar Kuhl; Jakob Voelkl; Florian Lang; Heinrich Brinkmeier
Journal:  Pflugers Arch       Date:  2014-11-14       Impact factor: 3.657

2.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

3.  ATOH8: a novel marker in human muscle fiber regeneration.

Authors:  Anne-K Güttsches; Ajeesh Balakrishnan-Renuka; Rudolf André Kley; Martin Tegenthoff; Beate Brand-Saberi; Matthias Vorgerd
Journal:  Histochem Cell Biol       Date:  2014-12-17       Impact factor: 4.304

4.  Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose-dependent manner through modulation of dystrophin.

Authors:  Gianna Móes Albuquerque-Pontes; Heliodora Leão Casalechi; Shaiane Silva Tomazoni; Andrey Jorge Serra; Cheila de Sousa Bacelar Ferreira; Rodrigo Barbosa de Oliveira Brito; Brunno Lemes de Melo; Adriane Aver Vanin; Kadma Karênina Damasceno Soares Monteiro; Humberto Dellê; Lucio Frigo; Rodrigo Labat Marcos; Paulo de Tarso Camillo de Carvalho; Ernesto Cesar Pinto Leal-Junior
Journal:  Lasers Med Sci       Date:  2017-12-05       Impact factor: 3.161

5.  Coronary adventitial cells are linked to perivascular cardiac fibrosis via TGFβ1 signaling in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Nicholas Ieronimakis; Aislinn L Hays; Kajohnkiart Janebodin; William M Mahoney; Jeremy S Duffield; Mark W Majesky; Morayma Reyes
Journal:  J Mol Cell Cardiol       Date:  2013-08-01       Impact factor: 5.000

Review 6.  Modifier genes and their effect on Duchenne muscular dystrophy.

Authors:  Andy H Vo; Elizabeth M McNally
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

Review 7.  Wasting mechanisms in muscular dystrophy.

Authors:  Jonghyun Shin; Marjan M Tajrishi; Yuji Ogura; Ashok Kumar
Journal:  Int J Biochem Cell Biol       Date:  2013-05-11       Impact factor: 5.085

8.  Mitochondrial alterations and oxidative stress in an acute transient mouse model of muscle degeneration: implications for muscular dystrophy and related muscle pathologies.

Authors:  Renjini Ramadasan-Nair; Narayanappa Gayathri; Sudha Mishra; Balaraju Sunitha; Rajeswara Babu Mythri; Atchayaram Nalini; Yashwanth Subbannayya; Hindalahalli Chandregowda Harsha; Ullas Kolthur-Seetharam; Muchukunte Mukunda Srinivas Bharath
Journal:  J Biol Chem       Date:  2013-11-12       Impact factor: 5.157

9.  Effects of endurance exercise and doxorubicin on skeletal muscle myogenic regulatory factor expression.

Authors:  Colin J Quinn; David S Hydock
Journal:  Muscles Ligaments Tendons J       Date:  2018-01-10

Review 10.  The quasi-parallel lives of satellite cells and atrophying muscle.

Authors:  Stefano Biressi; Suchitra D Gopinath
Journal:  Front Aging Neurosci       Date:  2015-07-22       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.